indication

Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor

TOKYO, Mar 28, 2022 – (JCN Newswire via SEAPRWire.com) – Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca (Generic name: Filgotinib, “Jyseleca”), Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan. In September 2020,... » read more

AbbVie and Eisai Announce an approval for additional indication of HUMIRA

TOKYO, Nov 27, 2020 – (JCN Newswire) – AbbVie GK and Eisai Co., Ltd. today announced an approval of additional indication of HUMIRA (generic name: adalimumab [recombinant], hereafter “HUMIRA”), a fully human anti-TNFalpha monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter “PG”). HUMIRA was granted orphan drug designation for the treatment of PG in... » read more